Preferences in Cyclin-Dependent Kinase 4/6 Inhibitors for Advanced Breast Cancer Among Medical Oncologists in Latin America - PubMed
3 hours ago
- #Advanced Breast Cancer
- #Latin America
- #CDK4/6 inhibitors
- CDK4/6 inhibitors (CDK4/6i) are standard care for hormone receptor-positive, HER2-negative advanced breast cancer.
- A survey of 116 oncologists from 15 Latin American countries revealed Ribociclib as the preferred CDK4/6i (56.8%), mainly due to its overall survival benefit.
- Abemaciclib was favored in cases of endocrine resistance, CNS metastases, and patients with cardiac or hepatic comorbidities.
- Palbociclib was preferred for geriatric and male patients.
- Access to CDK4/6i is uneven at the institutional level despite high national availability.
- 54.3% of private practice oncologists reported differing prescribing patterns for publicly insured patients, compared to 22.6% of public sector oncologists.
- Institutional access barriers persist in Latin America, highlighting the need for broader integration into public formularies and real-world data generation.